Combination targeted therapy for advanced lung cancer with egfr and tp53 mutations
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (the most common type) with an EGFR mutation (19 deletion or L858R) and a TP53 mutation—your doctor will confirm this.
- You are between 18 and 85 years old and have not yet started treatment for advanced disease.
- You are in good overall health (able to do light activity) with a life expectancy of more than 6 months.
- Your kidney, liver, and blood counts are within normal limits.
- Any brain metastases are treated and stable without symptoms for at least 4 weeks.
- You do not have high blood pressure that is not controlled, bleeding issues, or unhealed wounds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral drugs, sunvozertinib and anlotinib, taken together for people with advanced lung cancer that has an EGFR mutation and has gotten worse after EGFR targeted therapy. The goal is to see if this combination helps control cancer better than standard options.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
Hear when a new Anlotinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.